The Combined Antibiotic Therapy for Carbapenem Resistant Klebsiella Pneumoniae

• Status: Unknown status
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The infection of carbapenem resistant klebsiella pneumoniae (CRKP) is increasingly serious.Based on the early experimental basis and relevant research background,this study intends to separate and purify the CRKP from the bronchoalveolar lavage fluid (BALF) of the clinical patients.Designed by checkerboard assay and time-kill assay(TKA)，this study can explore the best combination therapy based on carbapenems.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai 10th People's Hospital
• Treatments: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Fosfomycin; Meropenem; Polymyxin B; Polymyxins; Tigecycline

Criteria

Inclusion Criteria:

• age from 18 to 90.

• infected with CRKP firstly .

Exclusion Criteria:

• APACHE II score > 35

• Vital signs are unstable

• Unable to tolerate fiberoptic bronchoscopy